Ken Griffin’s Enliven Therapeutics ELVN Stock Holding History
Bought
Maintained
Sold
Other funds holding ELVN
Ken Griffin's ELVN Position: Q3 2026 in Review
Ken Griffin reduced its Enliven Therapeutics (ELVN) stake by 40% in Q3 2026, selling an estimated $44.9M and leaving 1,244,524 shares worth $57M. The position accounts for 0.01% of the portfolio, ranked #1437.
Ken Griffin first reported a position in ELVN in Q1 2020 and has held it in 18 quarters since. The position peaked at $105M in Q2 2026. 216 funds tracked by Wall St. Rank hold ELVN as of Q3 2026.
- Ken Griffin held 1,244,524 shares of Enliven Therapeutics worth $57M as of Q3 2026.
- Ken Griffin sold 824,468 Enliven Therapeutics shares in Q3 2026, an estimated $44.9M.
- Enliven Therapeutics made up 0.01% of Ken Griffin's portfolio in Q3 2026, its #1437 holding.
- Ken Griffin first reported a position in Enliven Therapeutics in Q1 2020 and has held it in 18 quarters since.
- Ken Griffin's Enliven Therapeutics position peaked at $105M in Q2 2026.
- 216 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q3 2026.
Based on Citadel Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.